Hawaii Employer-Union Health Benefits Trust Fund

(All applicable to the EUTF non-Medicare retiree plan only)

1. Added the anti-psychotic class to the Generic Step Therapy Program effective April 1, 2025. Existing members using an anti-psychotic drug will be grandfathered.
2. Implemented the Basic Control Formulary effective July 1, 2025, where utilization management was added to non-preferred products in ten specific drug classes.
3. Implemented Hyperinflation Management effective July 1, 2025, where hyperinflated drugs that have readily available, clinically appropriate and more cost-effective alternatives are excluded.
4. Revised prior authorization criteria for antidiabetic GLP-1s and added a cumulative fill edit on antidiabetic and weight loss GLP-1s simultaneously effective July 1, 2025. Antidiabetic GLP-1s include Ozempic, Mounjaro, Rybelsus, Trulicity, and Victoza, and weight loss GLP-1s include Wegovy and Zepbound.
5. Added prior authorization requirements for non-specialty dermatologic products effective January 1, 2026. Existing members using a non-specialty dermatologic product will be grandfathered and will not need to obtain prior authorization.